PriceTargets.com logo

Taiwan Liposome - TLC Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$7.00 As of 09/28/2021 01:00 AM ET
+0 (0.00%)
Get New Taiwan Liposome Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TLC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TLC

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Taiwan Liposome in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $7.00.

This chart shows the closing price for TLC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Taiwan Liposome. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/1/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/29/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/27/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/25/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/24/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/13/2021HC WainwrightDowngradeBuy ➝ Neutral$11.00 ➝ $7.50Medium
7/7/2021LaidlawDowngradeBuy ➝ HoldHigh
10/29/2020Cantor FitzgeraldReiterated RatingOverweightLow
10/29/2020HC WainwrightReiterated RatingBuyHigh
8/17/2020HC WainwrightReiterated RatingBuy$11.00Medium
6/1/2020Cantor FitzgeraldBoost TargetOverweight$10.00 ➝ $12.00High
2/13/2020HC WainwrightReiterated RatingBuy$11.00Medium
2/12/2020Cantor FitzgeraldLower TargetOverweight$11.00 ➝ $10.00Low
12/23/2019Cantor FitzgeraldInitiated CoverageOverweight$11.00Low
10/23/2019HC WainwrightReiterated RatingBuy$10.00Low
10/18/2019Cantor FitzgeraldReiterated RatingOverweightLow
9/24/2019HC WainwrightSet TargetBuy$10.00Medium
6/20/2019Robert W. BairdInitiated CoverageOutperform ➝ OutperformLow
5/20/2019HC WainwrightReiterated RatingBuy$10.00Low
(Data available from 4/24/2019 forward)

News Sentiment Rating

0.12 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 15 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
9/27/2023
  • 0 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/27/2023
  • 1 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/26/2023
  • 7 very positive mentions
  • 12 positive mentions
  • 4 negative mentions
  • 2 very negative mentions
Mentions as of
12/26/2023
  • 0 very positive mentions
  • 14 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
1/25/2024
  • 3 very positive mentions
  • 15 positive mentions
  • 4 negative mentions
  • 2 very negative mentions
Mentions as of
2/24/2024
  • 7 very positive mentions
  • 18 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
3/25/2024
  • 3 very positive mentions
  • 16 positive mentions
  • 4 negative mentions
  • 2 very negative mentions
Mentions as of
4/24/2024

Current Sentiment

  • 3 very positive mentions
  • 16 positive mentions
  • 4 negative mentions
  • 2 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Taiwan Liposome logo
Taiwan Liposome Co., Ltd. engages in the research and development of lipid-based formulation drugs. Its products are used for pain management, eye disease treatment, and cancer treatment. The company was founded by Kee Lung Hong on November 10, 1997 and is headquartered in Taipei, Taiwan.
Read More

Today's Range

Now: $7.00
Low: $7.00
High: $7.09

50 Day Range

MA: $7.10
Low: $6.76
High: $7.63

52 Week Range

Now: $7.00
Low: $4.07
High: $7.70

Volume

12,421 shs

Average Volume

133,095 shs

Market Capitalization

$294.54 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.99

Frequently Asked Questions

What sell-side analysts currently cover shares of Taiwan Liposome?

The following equities research analysts have issued stock ratings on Taiwan Liposome in the last year:
View the latest analyst ratings for TLC.

What is the current price target for Taiwan Liposome?

0 Wall Street analysts have set twelve-month price targets for Taiwan Liposome in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Taiwan Liposome in the next year.
View the latest price targets for TLC.

What is the current consensus analyst rating for Taiwan Liposome?

Taiwan Liposome currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for TLC.

What other companies compete with Taiwan Liposome?

Other companies that are similar to Taiwan Liposome include Kamada, Neoleukin Therapeutics, Erasca, Verrica Pharmaceuticals and Contineum Therapeutics. Learn More about companies similar to Taiwan Liposome.

How do I contact Taiwan Liposome's investor relations team?

Taiwan Liposome's physical mailing address is 11TH FLOOR-1 YUANQU STREET NANGANG DISTRICT, TAIPEI CITY F5, 11503. The company's listed phone number is 886226557377 and its investor relations email address is [email protected]. The official website for Taiwan Liposome is www.tlcbio.com. Learn More about contacing Taiwan Liposome investor relations.